The PLC-derived organoids developed in this study can highly recapitulate the characteristics of the two most common subtypes of liver cancer, including histological featuresand genetic and transcriptomic traits, and can help determine patient-specific drug sensitivity. This evidence concerns the gene HSPG2 and liver cancer.